Lorem ipsum dolor sit amet consectetur odio vel nunc platea orci quis dolor ac aliquet in sit viverra et neque sit sit eniim.
TRV-01 is the only technology designed to address the root causes of diabetic foot disease.
Triovance, one of eight private company finalists in the highly competitive.
Triovance has been selected for the INCIDE Pharma & Healthtech Booster Program
Company is on track to move into the clinic with TRV-01, a genetically modified cellular dressing.
Triovance is honored to be presenting at the Startup Spotlight of the 26th American Society of Gene and Cell Therapy
This study evaluated a novel skin graft (TRV-01) developed to improve the wound healing process in a glycated microenvir
Explore our collection of 200+ Premium Webflow Templates
